- United States
- /
- Chemicals
- /
- NYSE:SCL
Is Stepan’s Russell 2000 Dynamic Index Inclusion (SCL) Altering The Investment Case For Investors?

- In June 2026, Stepan Company (NYSE:SCL) was added to the Russell 2000 Dynamic Index, increasing its exposure to index-linked investors.
- This index inclusion can meaningfully raise Stepan’s visibility in the market, potentially influencing trading activity and institutional ownership patterns.
- Now we’ll explore how Stepan’s addition to the Russell 2000 Dynamic Index could influence its existing investment narrative and outlook.
We've uncovered the 9 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Stepan Investment Narrative Recap
To own Stepan, you need to believe in its ability to turn recent earnings weakness, including the Q1 2026 loss, into healthier cash generation and margin recovery. The Russell 2000 Dynamic Index inclusion should help liquidity and visibility, but it does not materially change the near term focus on restoring profitability or the key risk around pressured margins and cash flow.
The recent Q1 2026 earnings release, showing US$604.51 million in sales but a net loss of US$41.41 million, is highly relevant when thinking about this index addition. Higher index exposure may bring more attention to how Stepan manages working capital, raw material costs and the ramp up benefits from investments such as Pasadena, especially as investors watch for progress on earnings stabilization.
However, investors should also be aware that rising raw material costs in Surfactants could...
Read the full narrative on Stepan (it's free!)
Stepan's narrative projects $2.8 billion revenue and $137.8 million earnings by 2029. This requires 5.7% yearly revenue growth and a $152.0 million earnings increase from -$14.2 million today.
Uncover how Stepan's forecasts yield a $75.00 fair value, a 33% upside to its current price.
Exploring Other Perspectives
Three Simply Wall St Community fair value estimates sit between US$32 and about US$153, underscoring how far apart individual views can be. Against that wide range, concerns about negative free cash flow and margin pressure in Surfactants give you important context as you compare these different viewpoints on Stepan’s future performance.
Explore 3 other fair value estimates on Stepan - why the stock might be worth 43% less than the current price!
Decide For Yourself
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Stepan research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- Our free Stepan research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Stepan's overall financial health at a glance.
Seeking Other Investments?
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- The latest GPUs need a type of rare earth metal called Dysprosium and there are only 31 companies in the world exploring or producing it. Find the list for free.
- Find 45 companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NYSE:SCL
Stepan
Produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products in the United States, France, Poland, the United Kingdom, Brazil, Mexico, and internationally.
Undervalued with moderate growth potential.
Similar Companies
Market Insights
Weekly Picks

Giftify ($GIFT): A Small-Cap Incentives Platform with More ScaleThan Its Valuation Suggests

Quantifying the Transition: Why Lululemon’s Moat Remains Intact

Warren Buffett Just Bet $10 Billion on Google. The Catch? You May Already Be Too Late.

AI-Powered Veeva Systems Poised for Solid Growth Amid Regulatory Stability
Recently Updated Narratives
iShares Gold Trust will Boost Future PE by 2.7% over Five Years
Why I Invest in SIPEF?
Kucingko Berhad: Fundamentals Show Early Recovery as Creative Content Expansion Gains Traction
Popular Narratives

Mastercard: The Best Dividend Stock You're Ignoring

Adobe: A Probabilistic Case for Undervaluation


